Could a diabetes drug boost pregnancy success in women with PCOS?

NCT ID NCT07687667

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This trial investigates whether giving obese women with polycystic ovary syndrome (PCOS) a GLP-1 receptor agonist (a drug that helps control appetite and blood sugar) along with healthy lifestyle education for 12 weeks before starting fertility treatment can improve their chances of a successful pregnancy. The study compares this approach to the standard drug metformin plus lifestyle education. The main goal is to see if more women achieve an ongoing pregnancy beyond 20 weeks. Participants are women aged 18-40 with PCOS and a BMI between 28 and 35 who wish to conceive.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
GLP-1 receptor agonist (a drug that helps control blood sugar and appetite)
What this could lead to
If it works, this approach could boost live birth rates for obese women with PCOS, offering a new pre-fertility treatment strategy.
What could go wrong
This is a mid-stage trial, so results are not guaranteed. GLP-1 drugs can cause nausea, vomiting, or other side effects, and the benefit over standard metformin may be small or absent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFERTILITY, FEMALE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking University Third Hospital

    Beijing, Beijing Municipality, 100191, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.